Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.18 +0.10 (2.45%)
price chart
Arena Pharmaceuticals, Inc. Earnings: Looking for More
Most biotech investor would be happy with 30% quarter-over-quarter prescription growth in a market that didn't grow much. But for Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq, the growth is coming off such a small base that it's hard to get too excited.
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows  Zacks.com
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 ...  MarketWatch
Related articles »  
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and VIVUS's (NASDAQ: VVUS ) Qsymia reported a combined 283,000 prescriptions ...
Arena And Vivus Investors Need To Watch Orexigen  Seeking Alpha (registration)
Related articles »  
Why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Rising?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) surged as much as 6.6%. It was a welcome reprieve for Arena shareholders, who had seen the stock lose 25% of its value this year before today's gains.
Arena Pharmaceuticals, Inc., Loews Corporation, and Sysco Corporation ...
As Capitol Hill keeps its eyes closely trained on November elections, Wall Street's attention is elsewhere as earnings season continues this week.
Related articles »  
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report).
Geron Corp (NASDAQ:GERN) Skyrockets on Unusual Volume - Arena ...  StreetWise Report
Arena Pharmaceuticals Short Interest Down 5.2% in October (ARNA)  Ticker Report
Related articles »  
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma ...
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus ...
Related articles »  
Arena Offers Tease On Belviq And Phentermine (ARNA)
Arena announced that the 12 week study involving 238 patients met the safety endpoints, but the company stopped short of announcing the results of weight loss, opting to save that data for the Obesity Week Conference next week.
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot ...  MarketWatch
Related articles »  
Morning Investor Watch: Arena Pharmaceuticals, Inc. (ARNA), Hewlett-Packard ...
Arena Pharmaceuticals, Inc. (ARNA) of the Healthcare sector has a change from open of 0.000% since the opening bell today with a volume of 277,364 shares.
Belviq For Smoking Cessation - Sizzle Or Smolder? (ARNA)
Belviq, from Arena Pharmaceuticals (NASDAQ:ARNA) was recently involved in an early clinical trial as a possible aid to smoking cessation.
Related articles »